Issued 2026-08-13 at $2.34 · now $2.30 (2026-08-13, −1.7% since)
Based on its own history, a month from the 2026-08-13 close, HURA has typically landed between $1.34 and $3.96 — a range of −42.8% to +69.1% from the issuance price $2.34.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
3,363 overlapping 1 month windows · 2013-02-22 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($2.34) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where HURA has typically landed a month from the 2026-08-13 close of $2.34 — the range is history, not a prediction.
- now $2.3 (-1.7%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.11 (-9.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.7–$2.51
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.34–$3.96
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-04-11 | −69.5% | −69.5% | +0.0% |
| 2019-08-02 | −64.8% | −64.8% | +3.0% |
| 2019-07-31 | −64.5% | −64.5% | +0.0% |
| 3 best | |||
| 2023-10-10 | +356.1% | +0.0% | +477.6% |
| 2023-10-02 | +351.0% | −21.9% | +351.0% |
| 2023-10-06 | +323.9% | −14.6% | +393.0% |
3,363 overlapping windows · 2013-02-22 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2027-03-31 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~14 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.